VTRSViatris Inc.

$17B

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.8B-3.1% YoY

Gross Profit

$1.4B38.1% margin

Operating Income

-$240M-6.3% margin

Net Income

-$326M-8.6% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

+3.6%

Cash Flow

Operating Cash Flow

$379M

Free Cash Flow

$320M

Stock-Based Comp.

$35M

Balance Sheet

Total Assets

$45.3B

Total Liabilities

$25.8B

Stockholders' Equity

$19.5B

Cash & Equivalents

$917M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.8B	$3.9B	-3.1%
Gross Profit	$1.4B	$1.6B	-10.1%
Operating Income	-$240M	$369M	-165.0%
Net Income	-$326M	$264M	-223.6%

Revenue Segments

Brands

$2.4B62%

Generics

$1.4B38%

Geographic Segments

Developed Markets Segment

$2.3B61%

Emerging Markets Segment

$578M15%

Greater China Segment

$539M14%

Japan, Australia and New Zealand Segment

$350M9%

VTRS Q2 2024 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena